Bicara Therapeutics (NASDAQ:BCAX) is developing tumor-targeting bifunctional antibodies, with its lead candidate ficerasfusp alfa designed to address both EGFR and TGF-beta biology in cancer, company ...
Bicara Therapeutics (NASDAQ:BCAX) outlined its clinical and development strategy for its lead bifunctional antibody program, ...
Transforming growth factor beta 1 (TGFB1), also known as TGF-β1, CED, DPD1, and TGFB, is a polypeptide member of the transforming growth factor beta superfamily of cytokines. It is a secreted protein ...
For years, scientists have thought that TGF-Beta, a signaling protein that holds sway over an astonishing array of cellular processes from embryonic development to cancer, could only do its work once ...
Barclays 28th Annual Global Healthcare Conference March 10, 2026 11:30 AM EDTCompany ParticipantsRyan Cohlhepp - ...
We are pleased to present additional data that further underscore the wide-ranging therapeutic potential of rinvatercept,” said Jasbir S. Seehra, President and Chief Executive Officer of Keros. “These ...
TCGFB, a private biotech founded by healthcare VC The Column Group, is tapping California biotech Surrozen to discover antibodies for idiopathic pulmonary fibrosis, according to a Nov. 4 release.
Investigating the association of WNT pathway dysregulation and young-onset colorectal cancer. This is an ASCO Meeting Abstract from the 2024 ASCO Gastrointestinal Cancers Symposium. This abstract does ...
Transforming Growth Factor Beta (TGF‐β) signalling pathways are integral to a wide array of cellular processes, ranging from embryonic development to tissue homeostasis and immune regulation. TGF‐β ...
When it comes to cancer metastasis, it takes two to tango. That was one of the key findings of a new study led by researchers at Memorial Sloan Kettering Cancer Center (MSK): The TGF-beta and RAS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results